A 2018 critique of 16 research of cannabis-primarily based medicines for neuropathic suffering, nearly all of which examined a cannabinoid planning known as nabiximols (manufacturer name Sativex; a mouth spray that contains both equally THC and CBD that's accepted in certain countries but not in The us), located lower- to moderate-high quality evid